Advertisement
Singapore markets close in 6 hours

  • Straits Times Index

    3,300.18
    +7.49 (+0.23%)
     

  • Nikkei

    38,299.71
    +25.66 (+0.07%)
     

  • Hang Seng

    18,130.47
    +367.44 (+2.07%)
     

  • FTSE 100

    8,121.24
    -22.89 (-0.28%)
     

  • Bitcoin USD

    57,410.43
    -2,445.70 (-4.09%)
     

  • CMC Crypto 200

    1,256.90
    -82.17 (-6.14%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • Dow

    37,903.29
    +87.37 (+0.23%)
     

  • Nasdaq

    15,605.48
    -52.34 (-0.33%)
     

  • Gold

    2,328.80
    +17.80 (+0.77%)
     

  • Crude Oil

    79.39
    +0.39 (+0.49%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • FTSE Bursa Malaysia

    1,577.09
    +1.12 (+0.07%)
     

  • Jakarta Composite Index

    7,143.73
    -90.46 (-1.25%)
     

  • PSE Index

    6,644.26
    -56.23 (-0.84%)
     

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc.
·1-min read
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com